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Abstract
Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS (CYCLOPS) genes have been recently
identified as the most enriched class of copy-number associated gene dependencies in human cancer. These genes
are cell essential and render tumor cells highly sensitive to the expression of the remaining copy. Chromophobe renal
cell carcinoma (chRCC) is characterized by frequent chromosomal deletions, but the relevance of CYCLOPS genes in
this tumor subtype is unclear. We found 39 (31%) of 124 recently published candidate CYCLOPS genes (B. Paolella
et al., eLife 2017;6:e23268) located on 7 autosomes that are frequently lost in chRCC. GISTIC and RNA-seq data
obtained from the TCGA-KICHdatabase showed that 62%of theseCYCLOPSgenes had significantly lower expression
levels in sampleswith deletionof the respective gene. As copynumber (CN) lossof theCYCLOPSgeneSF3B1 (Splicing
factor 3B subunit 1) has been recently reported in 71% chRCC, we explored the relevance of SF3B1 CN alteration and
SF3B1 expression in a set of chRCC and additional oncocytic renal neoplasms. The frequency of SF3B1CN loss (65%)
was similar to that obtained from the TCGA-KICH database and correlated significantly with both lower SF3B1 mRNA
(P b .05) and protein expression (P b .001). Other tumor subtypeswith oncocytic cytoplasmhadnormalSF3B1CNand
displayed strong SF3B1 protein expression. These results suggest that CN loss of CYCLOPS genes is a characteristic
feature in chRCC. Since many CYCLOPS genes code for components of proteasomes and transcriptional regulation,
their alteration could make chRCC vulnerable to targeted drugs.
Translational Oncology (2019) 12, 1131–7
Introduction
In a recent study with 86 cancer cell lines, a class of genes was
identified, which render cells with hemizygous loss highly dependent
on the expression of the remaining copy [1]. As partial, but not
complete inactivation was shown to be compatible with cancer cell
survival, these genes were termed Copy number alterations Yielding
Cancer Liabilities Owing to Partial losS (CYCLOPS) genes, which
predominantly code for proteasome, spliceosome, and ribosome
components [1,2]
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Chromophobe renal cell carcinoma (chRCC) is a distinct histological
entity of RCC, which was first described by Thoenes et al. [3] and
accounts for approximately 5–7%of RCC [4]. In contrast to other renal
cancer subtypes, e.g. clear cell renal cell carcinoma (ccRCC) and
papillary RCC (pRCC), chRCCs are characterized by frequent loss of
chromosomes 1, 2, 6, 10, 13, 17, 21 and Y [4]. This leads to gene copy
number alterations that affect tumor suppressor genes, such as PTEN,
RB1 and p53, but also a high number of additional genes whose role
is considered non-oncogenic. chRCC have a relatively indolent biologic
behavior compared to ccRCC and pRCC [4–6]. However, several
studies have demonstrated that some patients with chRCC die of
metastatic disease and the survival of metastatic chRCC patients is
comparable to metastatic ccRCC [5,7]. It can be challenging to
distinguish chRCC from other renal cell neoplasms with oncocytic cells,
especially from renal oncocytoma and hybrid oncocytic/chromophobe
tumors (HOCT) [4].
Given the high frequency of chromosomal losses observed in
approximately 70% of chRCC [4], we hypothesized that CYCLOPS
genes play a critical role in the pathogenesis of this tumor subtype. We,
therefore, used The Cancer Genome Atlas (TCGA) and the data
published by Paolella et al. [1] to determine copy number (CN) and
mRNA expression levels of all CYCLOPS gene candidates being
relevant for chRCC. As CN loss of the CYCLOPS gene SF3B1, which
code Splicing Factor 3B subunit 1, was reported in 71% chRCC [1], we
analyzed SF3B1CN alterations, mRNA and protein expression levels in
our own set of chRCC, hybrid oncocytic/chromphobe tumors
(HOCT) and oncocytic papillary renal cell carcinoma (opRCC).
Materials and Methods
Data Sets and Databases
Corresponding clinical information of TCGA-KICH samples were
obtained from TCGA Data Portal (https://portal.gdc.cancer.gov/). In
the TCGA-KICH dataset, there are 66 primary chRCCs with copy
number variation and RNA-seq data [8]. Digital whole slide images of
TCGA cases were reviewed by using the Cancer Digital Slide Archive
(http://cancer.digitalslidearchive.net/). The demographic and clinical
characteristics for the selected 66 patients are summarized in Table 1.
A list of 124 CYCLOPS gene candidates identified by Paolella et al.
[1] was used to identify those genes with frequent CN loss in chRCC.
The manually curated Kyoto Encyclopedia of Genes and Genomes
(KEGG) database was used via STRING in order to determine the
enrichment of the genes of interest in KEGG pathway maps [9].
Publically available Level 3 TCGA data were downloaded from the
FIREBROWSE database (http://firebrowse.org/) including the GIS-
TIC2 (level 4) CN analysis data and NGS-based RNA-sequencing
(RNA-seq) data as previously described [10]. The gene-level table
consisting of discrete values indicating loss (b0) or no loss (≥0) for each
CYCLOPS gene for each sample was obtained from the GISTIC2 data.
This was used as a grouping onwhich the expression levels were compared
correcting for multiple comparisons.
Swiss Tumor Samples
We selected 10 opRCCs, 37 chRCCs, 14 renal oncocytomas, and
6 HOCTs from the archive of the Department of Pathology and
Molecular Pathology of the University Hospital Zurich, Switzerland.
Tumors were staged according to the TNM staging system [11]. The
demographic and clinicopathological characteristics for the 37
chRCC are summarized in Table 1. The study was approved by the
Cantonal Ethics Committee of Zurich (KEK-ZH-Nr. 2013–0629;
KEK-ZH-Nr. 2011–72/4). The retrospective use of normal and
tumor tissues of RCC patients is in accordance with the Swiss Law
(“Humanforschungsgesetz”), which, according to Article 34, allows
the use of biomaterial and patient data for research purposes without
informed consent under certain conditions that include the present
cases. Law abidance of this study was reviewed and approved by the
ethics commission of the Canton Zurich.
All tumors were reviewed by two pathologists (R.O. and H.M.)
and histologically classified according to the World Health
Organization guidelines [4]. ChRCCs were defined as tumors
composed of large polygonal cells with clarified, so-called “pale cell”
or eosinophilic cytoplasm with distinct cell border, perinuclear halo
and irregular (raisinoid) nuclei. All chRCC were positive for CK7,
succinate dehydrogenase subunit B (SDHB) and fumarate hydratase
(FH) and negative for vimentin except for focal sarcomatoid area of
one chRCC. Renal oncocytomas were defined as tumors composed of
oncocytes (round nuclei with prominent nucleoli, eosinophilic
granular cytoplasm) without raisinoid nuclear irregularity, and
Cytokeratin 7 (CK7) negative or focal expression in central scar
area. HOCTs were defined as tumors with overlapping histology
between oncocytoma and chRCC. opRCCs were defined as papillary
RCC with voluminous, finely granular, deeply eosinophilic cytoplasm
and oncocytoma-like round to oval, regular, low grade nuclei. Their
nuclei are single-layered and linearly aligned.
OncoScan® CN Assay
Tumor areas displaying N80% cancer cell portion were marked on the
hematoxylin and eosin slides. DNA from formalin-fixed
paraffin-embedded (FFPE) tumor tissue samples was obtained by
punching 4 to 6 tissue cylinders (diameter 0.6 mm) from each sample.
DNA extraction from FFPE tissue was done as described [12]. DNAwas
quantified by the fluorescence-based Qubit dsDNA HS Assay Kit.
Genome-wide DNA copy-number alterations and allelic imbalances of
37 chRCC, 4 HOCTs and 8 opRCCs were analyzed by Affymetrix
OncoScan® CNV FFPE Assay Kit (Affymetrix). The samples were
processed by IMGM Laboratories GmbH (Martinsried, Germany) for
CNV determination. The data were analyzed by the OncoScan Console
(Affymetrix) and Nexus Express (Biodiscovery, Inc. CA, USA) softwares
using Affymetrix TuScan algorithm. All array data were also manually
reviewed for subtle alterations not automatically called by the software.
Immunohistochemistry (IHC)
FFPE sections (2 μm) were transferred to glass slides and treated using
Ventana Benchmark XT andBondmax (LeicaMicrosystems) automated
systems. Antibodies and protocols are listed in Supplementary Table 1.
Table 1. Clinical data from two chRCC patient cohorts.
Characteristics Swiss TCGA-KICH
Patient no. 37 66
Age range (median) 18–86 (61) 17–86 (50)
Female 12 (32.4%) 27 (40.9%)
Male 25 (67.6%) 39 (59.1%)
pT or T Stage *
1 24 (64.9%) 21 (31.8%)
2 7 (18.9%) 25 (37.9%)
3 6 (16.2%) 18 (27.3%)
4 0 (0%) 2 (3.0%)
* Swiss dataset: pT stage, TCGA-KICH: T stage.
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Immunohistochemical evaluation was conducted by two pathologists
(R.O. and H.M.) blinded to the clinical data. Immunostained tissue
sections were scanned using the NanoZoomer Digital Slide Scanner
(Hamamatsu Photonics K.K., Shizuoka, Japan). Non-neoplastic cells
(e.g. proximal and distal renal tubular epithelial cells, inflammatory
cells, fibroblasts, and endothelial cells) were used as internal positive
control. SF3B1 expression was evaluated based on the percentage of
positive cells and staining intensity using the Histoscore (H-score) as
described previously [13]. The percentage of cells at different staining
intensities was determined by visual assessment, thereafter the score was
calculated using the formula 1 × (% of 1+ cells) + 2 × (% of 2+
cells) + 3 × (% of 3+ cells). The final score is on a continuous scale
between 0 and 300. Samples were grouped in tumors with low
(H-score ≤ 200) or high (H-scoreN 200) SF3B1 expression.
siRNA knockdown of SF3B1 in HEK293T cells was used for
antibody validation. siRNAs were transfected into HEK293T cells
using Lipofectamine-RNAiMAX reagent (Invitrogen) according to the
manufacture's protocol. In brief, 250′000 HEK293T cells were seeded
into a 6 well-plate. After 24 hours, reverse transient transfection was
done using 100 nM siRNAAllstars control and siSF3B1 (SI04161766)
(Qiagen) with 5ul Lipofectamine-RNAiMAX per well. Two days later
the cells were harvested. Cell blocks were prepared as described
previously [14] and subjected to immunohistochemistry.
Taqman Assay
RNA extraction from 19 FFPE chRCC was performed using
Maxwell® 16 Tissue DNAPurification Kit (Promega). RNA quality was
measured with RNA Qubit™ RNA HS Assay Kit (ThermoFisher).
cDNA was prepared using Superscript IV Vilo Mastermix 50 Rxns
(Thermo Fisher). The quantitative measurements were performed
using the Taqman Fast Advanced master mix (Thermo Fisher) with
20 ng/μL ng of cDNA in each technical duplicate and the cycling
parameters according to the protocol on a ViiA7 (Thermo Fisher). The
thermal cycler profile was as follows: 20 seconds at 95 °C, 40 cycles of
1 second at 95 °C and 20 seconds at 60 °C. All reactions were performed
in duplicates. Primer and probe set assay IDs for the TaqMan assays
were Hs00961640_g1 for SF3B1 and Hs03929097 for GAPDH,
(ThermoFisher). Normal tissue was used to normalize the quantitative
analysis of all samples. The Ct value for each sample was calculated with
the ΔΔCt-method, and the fold expression changes (tumor versus
normal) were calculated using the 2−ΔΔCT method.
Statistical Analysis
All statistical analyses were done using R, 3.4.1 (R Foundation for
Statistical Computing, Vienna, Austria) and the plugin EZR (Saitama
Medical Center, Jichi Medical University, Saitama, Japan). The Welch
two sample t-test was used when comparing the expression of CYLOPS
genes between samples with loss and no loss. The P-values obtained
where then corrected for multiple testing using the Benjamini &
Hochberg method. The Welch's t-test, the Mann–Whitney U test and
Pearson's correlation coefficient were used to assess associations between
continuous and categorical variables. The paired t-test was used for
paired normal and tumor data.P values b.05 were considered statistically
significant.
Results
CYCLOPS Genes in Chromophobe Renal Cell Carcinoma
By focusing on genome-wide CN-associated gene dependencies
(cell viability after gene suppression), Paolella et al. [1] identified 124
Figure 1. a) Protein–protein interaction of 37 CYCLOPS genes in chRCC constructed using KEGG enriched pathway and STRINGR
databases. Red: Proteasome; blue: Spliceosome; green and yellow: Gene/RNA regulation and processing. b) Protein–protein interaction
of 23 CYCLOPS genes lower expressed due to CN loss.
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CYCLOPS genes, which fulfilled this criterion. Thirty-nine of the
124 CYCLOPS genes were located on the seven most frequently lost
chromosomes in chRCC: 1, 2, 6, 10, 13, 17, and 21. These 39 genes
were deemed to be the most relevant for this chRCC. The list of the
genes shown in Supplementary Table 2 is a modified extract of the
gene list shown in supplementary file 1B of Paolella et al. [1]. Protein
functions and cellular pathways were from the National Center for
Biotechnology Information (NCBI) database.
CYCLOPS Copy Number and Gene Expression
Two of the 39 CYCLOPS genes were read-through transcripts and
removed from further analysis. The proteasome and spliceosome
KEGG pathways were enriched when considering the remaining 37
genes (Figure 1A). Notably, the gene products of 19 (51%) genes are
involved in RNA transcription/processing and proteasomes. Of the 37
CYCLOPS genes, 23 (62%) had significantly lower (adjusted P b .05)
mRNA expression when comparing samples experiencing a single allele
loss of the respective gene and those with no loss. The result of
the CYCLOPS gene expression analysis is shown in Supplementary
Table 3. When taking the 23 genes showing a significantly reduced
expression, mRNA transport and surveillance pathways were enriched
along with the proteasome pathway (Figure 1B).
SF3B1 Copy Number and Expression Analysis in chRCC and Other
Oncocytic Renal Neoplasms. Although being frequently affected by
CN loss [1], its influence on expression level of SF3B1 RNA and
protein in chRCC have not been investigated thus far. For this
purpose we first analyzed 37 chRCC using OncoScan FFPE assay. As
expected, the majority of cases revealed loss of autosomes 1, 2, 6, 10,
13, 17, and 21 (Figure 2). Twenty-four of 37 (65%) tumors showed
loss of SF3B1, which is located on chromosome 2. Neither 4 HOCT
nor 8 oncocytic papillary RCC showed SF3B1 CN alteration
(Supplementary Figure 1). The proportion of CN losses in the
TCGA-KICH dataset was similar with 47 of 66 (71%) chRCC
samples experiencing a SF3B1 CN loss.
Association of CN Loss and Reduced SF3B1 mRNA Expression. We
evaluated SF3B1mRNA expression in 19 matched normal kidney and
cancer tissue samples from the Swiss cohort by Taqman assay. Nine
chRCCs had SF3B1 CN loss and 10 chRCCs were without SF3B1
CN loss. The effect of CN on gene expression was analyzed by
comparing the mean mRNA fold-changes in chRCC with and without
Figure 2. Chromosomal copy number (CN) alterations detected by OnsoScan analysis of 37 chRCCs. a) Tumors with CN loss and
b) without CN loss. The location of SF3B1 on chromosome 2q33.1 is indicated by a dashed line. Blue: copy-number gain (Probemean log2
threshold: 0.3); red: copy-number loss (Probe mean log2 threshold: −0.3); yellow signals: copy-neutral, loss-of-heterozygosity.
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SF3B1 CN loss. SF3B1 mRNA transcription level was significantly
correlated with SF3B1 CN status (Figure 3A; Welch's t-test, P =
.043). This data were comparable with those obtained from
TCGA-KICH (see Supplementary Table 3). The mRNA levels in
tumors with SF3B1 CN loss were 50% reduced.
Association of CN Loss and Reduced SF3B1 Protein Expression. We
evaluated SF3B1 protein expression by immunohistochemistry of 10
normal kidney tissue samples and in 37 Swiss chRCC samples for
which we had available the SF3B1 CN status via OncoScan. To check
whether this antibody was applicable for immunostaining, we
performed siRNA-based knockdown of SF3B1 expression. Compared
to control siRNA transfected HEK293 cells, which have two intact
chromosomes 2 [15], the knockdown cells showed reduction of SF3B1
protein expression (Figure 4A).
In adjacent normal kidney tissue of 37 chRCC patients, SF3B1 was
strongly positive in nuclei of all normal kidney cells including
podocytes, mesangial cells, renal tubules, endothelial cells, interstitial
fibroblasts and immune cells (Figure 4B). The SF3B1 protein level
assessed by continuous H-score and binary evaluation using H-score
with cutpoint 200 was significantly lower in the tumors with SF3B1
CN loss than in the remaining chRCC (Figure 3B; Mann–Whitney U
test, P = .0004). Fifteen of 24 (63%) tumors with CN loss had reduced
SF3B1 positivity (immunoreactivity of 1+; H-score ≤200) and 12 of
13 (92%) tumors with neutral CN had normal SF3B1 expression levels
(immunoreactivity of 2+; H-score N200). No correlation was found
between SF3B1 protein expression and pT stage. Examples of
hematoxylin/eosin stained and immunostained chRCC are shown in
Figure 4, C–F. All renal oncocytomas, HOCTs and opRCCs showed
strong nuclear expression of SF3B1 (Figure 4, G–L).
Discussion
In this study, we demonstrate that copy number loss of CYCLOPS
genes is a characteristic and unique feature of chRCC.We show that the
7 autosomes, which are lost in themajority of chRCC, harbor one-third
of 124 CYCLOPS genes [1]. About half of these genes belong to
pathways regulated by proteasomes and the transcription machinery.
Gene expression analysis using TCGA-KICH data demonstrated that
CN loss led to significantly lower transcription levels of more than 60%
of the genes. This data suggest that in chRCC CN loss of CYCLOPS
genes accompanied by a reduction of expression makes tumor cells even
more vulnerable than CN loss alone.
CN loss of the CYCLOPS gene SF3B1 occurs most frequently in
chRCC [1]. As the influence of CN loss to SF3B1 protein
expression is yet unclear, we decided to analyze our own set of
chRCC by immunohistochemistry. Our comprehensive CN study
of chRCC demonstrated SF3B1 genomic loss in a large fraction of
chRCC (65%), which is consistent with TCGA data demonstrating
CN losses of SF3B1 in 71% chRCC [1,8]. Reduced SF3B1 mRNA
and protein expression was significantly associated with SF3B1 CN
loss in chRCC. These findings indicate that SF3B1 CN loss causes
reduced expression of SF3B1 in most chRCC. Potentially,
additional mechanisms of SF3B1 downregulation exist, since we
observed a few chRCC without SF3B1 CN loss but with reduced
SF3B1 expression. As SF3B1 mutations do not exist in chRCC
[1,8], SF3B1 mRNA and protein expression may be influenced by
post-transcriptional, translational and protein degradation regula-
tion in these tumors [16].
SF3B1 is a core component of the U2 small nuclear ribonucleo-
protein at the catalytic center of the spliceosome and contributes to
intron removal by anchoring pre-mRNA onto the spliceosome [17].
Previous studies have indicated that mutations or aberrant splicing
patterns in spliceosome components, including SF3B1, are associated
with different cancer phenotypes [1,17–20]. Interestingly, in patients
with myelodysplastic syndrome SF3B1 mutations lead to deregulated
expression and splicing of several DNA repair and DNA damage
response genes as well as of RNA-processing factors [21]. In regards to
chRCC, the decrease of CN loss mediated SF3B1 expression may
affect the splicing of transcripts involved in chromatin structure,
DNA repair and DNA damage response, thereby possibly providing
an explanation for the accumulation of elevated somatic mutation rate
and mutation signature of DNA mismatch repair deficiency seen in
this tumor type [8,22].
It was recently shown that SF3B1 is a HIF1α target [23].
Mechanistic and functional linkages between HIF1α, SF3B1, and
fructose metabolism by production of splice isoform ketohexokinase-C
(KHK-C) were shown in cardiac hypertrophy. KHK-C is the central
Figure 3. Association of SF3B1 mRNA and protein expression levels with SF3B1 copy number in Swiss chRCC cohort. a) Normalized
mean mRNA expression of SF3B1 in tumors with SF3B1 CN neutral and SF3B1 CN loss (Welch's t-test, P = .043; bars indicate standard
deviation). b). SF3B1 H-scores of chRCC without SF3B1 CN loss (mean 243.5). and with SF3B1 CN loss (mean165.4; Mann–Whitney U
test; P = .0004).
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fructose-metabolizing enzyme and KHK-C expression through the
HIF1α-SF3B1 axis promotes conversion of fructose carbon to lipids,
suppresses mitochondrial oxidative phosphorylation and increases
glycolysis [16]. In the TCGA-KICH dataset of chRCC we identified
a highly significant positive correlation between HIF1α and SF3B1
mRNA expression (Supplementary Figure 3). It is therefore tempting to
speculate that a SF3B1/HIF1α pathway exists in chRCC.
ChRCC, oncocytoma, and HOCT represent a spectrum of tumors
with oncocytic cells. A rare group of oncocytic papillary tumors has
also been described [24–26]. The biological behavior of these
oncocytic neoplasms ranges from benign (oncocytoma), low
malignant behavior (HOCT), to malignant (chRCC). The oncocytic
phenotype is mainly due to the accumulation of mitochondria. The
differential diagnosis between these oncocytic neoplasms is sometimes
extremely difficult on the basis of morphology alone. Several studies
reported that chromosome 2 loss is not present in oncocytoma
[27–30]. Our CN analysis showed no SF3B1 CN alteration in
HOCT and opRCC. For this reason, we expected generally stronger
SF3B1 protein expression in oncocytoma, HOCT and opRCC than
in the majority of chRCC in which only one gene copy of SF3B1
exists. In our current study, strongly positive SF3B1 protein
expression by IHC was observed in all renal oncocytomas, HOCTs
and opRCCs. Therefore, SF3B1 expression may help in the
differential diagnosis of oncocytic neoplasms.
As chromosome 2 loss hardly occur in clear cell and papillary RCC
[31,32], we used TCGA data to compare SF3B1 expression levels in
these two tumor subtypes with those in chRCC. As expected, SF3B1
mRNAwas significantly more abundant in clear cell and papillary RCC
(Supplementary Table 4) suggesting that attenuated SF3B1 expression
due to chromosome 2 loss in chRCC is unique for renal neoplasms.
In conclusion, we identified frequent CN loss combined with
reduced expression of many CYCLOPS genes as characteristic feature
for chRCC. Further studies taking advantage of the compromised
integrity of spliceosomes and RNA processing may reveal novel
strategies for the treatment of chRCC.
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